A review.Several clin. trials to treat Coronavirus 2019 (COVID-19) are in progress around the world.Some of them rely on clin. experience, whereas others include computational predictions.Here, we provide an overview of current efforts in the search for COVID-19 therapies, focusing on structural information of relevant targets.We elaborate on a robust pharmacol. rationale for the repurposing of existing drugs, highlighting key advantages of dual therapies with antiviral and anti-inflammatory activity.Furthermore, we provide a consensus list of mols. that could undergo preliminary randomized clin. trials against COVID-19.